| TB | No TB | Total | P value |
---|---|---|---|---|
 | 69 (7 %) | 900 (93 %) | 969 |  |
Age (at baseline) | ||||
 Median, IQR (years) | 5 (2–11) | 5 (2–9) |  |  |
  < 3 years | 31 (9) | 307 (91) | 338 | 0.07 |
Sex | ||||
 Male | 28 (6) | 460 (94) | 488 | 0.09 |
 Female | 41 (9) | 440 (91) | 481 |  |
Centre | ||||
 Entebbe | 16 (9) | 163 (91) | 179 | 0.35 |
 JCRC | 16 (6) | 248 (94) | 264 |  |
 Harare | 14 (6) | 243 (94) | 257 |  |
 PIDC | 23 (9) | 246 (91) | 269 |  |
Height (median IQR) | ||||
 Height-for-age Z score | −3.0 (−4.0 to –1.8) | −2.3 (−3.3 to –1.3) |  | <0.001 |
Weight (median IQR) | ||||
 Weight-for-age Z score | −2.8 (−4.1 to –1.8) | −1.8 (−2.8 to –0.9) |  | <0.001 |
WHO stage | ||||
 3 or 4 | 52 (8) | 561 (92) | 613 | 0.03 |
CD4 (median, IQR) | ||||
 CD4 % | 8 (5–13) | 13 (7–19) |  | 0.001 |
 CD4 counta | 136 (33–250) | 253 (93–405) |  | 0.07 |
Initial ART | ||||
 3TC ABC EFV | 6 (6) | 99 (94) | 105 | 0.03 |
 3TC ABC NVP | 24 (11) | 190 (89) | 214 |  |
 ZDV 3TC ABC EFV | 9 (4) | 217 (96) | 226 |  |
 ZDV 3TC ABC NVP | 30 (7) | 394 (93) | 30 |  |
Randomization | ||||
 A (3TC/ABC/NNRTI throughout) | 30 (9) | 289 (91) | 319 |  |
 B (3TC/ABC/NNRTI throughout, ZDV until week 36) | 24 (7) | 301 (93) | 325 |  |
 C (3TC/ABC/ZDV throughout, NNRTI until week 36) | 15 (5) | 310 (95) | 325 | 0.06 |
Randomization | ||||
 Clinical monitoring | 35 (7) | 449 (93) | 484 |  |
 Laboratory monitoring | 34 (7) | 451 (93) | 485 | 0.89 |